Earlydiagnostics Inc.
Agoura Hills, CA Doing business as Earlydx
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 30601 Agoura Rd #250, Agoura Hills, CA 91301, USA
- Website
- earlydx.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $1,994,911 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Topic 428 - NCI sbir transition to phase II solicitation FY 2023 | National Cancer Institute (NIH) | $1,994,911 | |
| Topic 428 "cloud-based liquid-biopsy platform for the cancer research data commons" | National Cancer Institute (NIH) | $395,918 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Methylscan for early detection of liver and lung cancer | National Cancer Institute (NIH) | $4,907,853 | |
| An accurate, non-invasive, and cost-effective methylome test for early cancer detection | National Cancer Institute (NIH) | $351,646 |
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| University Of California, LOS Angeles | U01CA285010 | $324,051 |
Similar vendors
About the company
Earlydiagnostics Inc., doing business as Earlydx, is a for-profit corporate entity that provides accurate, affordable, and non-invasive methods for early cancer detection, including a blood test called CancerRadar. Through federal contracts, Earlydx has provided research and development aligned with developing a cloud-based liquid-biopsy platform for the Cancer Research Data Commons. This $395,918 firm fixed price contract was awarded by the National Institutes of Health National Cancer Institute under the Small Business Innovation Research program. The contract has a total small business set aside designation and no major subcontractors were identified.
Through federal grants, Earlydx has provided research and development of a blood-based methylation profiling test called MethylScan that can detect and locate multiple types of cancer early. A $4.9 million project grant was awarded by the National Institutes of Health National Cancer Institute to optimize the MethylScan assay and workflow and clinically validate it for early detection of liver and lung cancer. Earlydx also received a $351,646 project grant to develop an accurate, non-invasive, and cost-effective methylome test for early cancer detection.
Quick answers
Is Earlydiagnostics Inc. registered in SAM.gov?
Yes. Earlydiagnostics Inc.'s SAM.gov registration is active through June 4, 2027.
What is Earlydiagnostics Inc.'s CAGE code?
Earlydiagnostics Inc.'s CAGE code is 87YY4, and its Unique Entity ID (UEI) is SGJ1NZDE89G4.
How much has Earlydiagnostics Inc. received in federal contracts?
Federal contracts obligated $1,994,911 to Earlydiagnostics Inc. in fiscal years 2023 through 2027.
What is Earlydiagnostics Inc.'s most recent federal award?
Earlydiagnostics Inc.'s most recent federal contract award is Topic 428 - NCI sbir transition to phase II solicitation FY 2023 (75N91023C00022), from National Cancer Institute (NIH), on August 15, 2023.
On GovTribe
See Earlydiagnostics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors